[Widening of possibilities of treatment of multiple sclerosis with the novel oral drug teriflunomide (aubagio)].
Teriflunomide is a novel oral medication for relapsing remitting multiple sclerosis (RRMS), which has demonstrated it's efficacy in relapse rate reduction.  It's efficacy has been confirmed by MRI results as well.
It is safe and well-tolerated, with mild and transitory side effects.  Nevertheless, risk management plan should be applied to minimize and monitor possible adverse events.
